Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc. (COEP): 13 pipeline candidates · 1 upcoming catalyst · ~9 mo cash runway. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
9.3 months
D/E 0.13 · 0% dilution
Lead: Phase 2
13 candidates
1 upcoming, next in ~3344d
N/A
A transparent, data-derived signal for Coeptis Therapeutics Holdings Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$102.1M
Cash
$5.2M
Quarterly Burn
$1.8M
Runway
9.3 mo
Revenue
$114K
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (13 candidates)
| Drug | Phase |
|---|---|
| Bortezomib | Phase 2 |
| Carfilzomib | Phase 1 |
| CD38-Diagnostic | Preclinical |
| CD38-GEAR-NK | Preclinical |
| CPT60621 | — |
| Daratumumab | Phase 2 |
| Daratumumab and Recombinant Human Hyaluronidase | Phase 1 |
| DVX201 (Unmodified Natural Killer Cells) | Phase 1 |
| Pomalidomide | Phase 2 |
| Selinexor | Phase 2 |
Showing 10 of 13 candidates. Sign up for full pipeline.
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
12
Total value held
$9.0M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 641,462 | $7.2M |
| geode capital management, llc | 53,093 | $596K |
| state street corp | 26,830 | $301K |
| vanguard fiduciary trust co | 24,573 | $276K |
| united capital financial advisors, llc | 20,000 | $224K |
| blackrock, inc. | 13,566 | $152K |
| northern trust corp | 12,219 | $137K |
| steward partners investment advisory, llc | 5,000 | $56K |
| vanguard global advisers, llc | 1,671 | $19K |
| morgan stanley | 201 | $2K |
Showing top 10 of 12 institutional holders of Coeptis Therapeutics Holdings Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Coeptis Therapeutics Holdings Inc.'s pipeline?
Coeptis Therapeutics Holdings Inc. (COEP) has 13 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Coeptis Therapeutics Holdings Inc.'s lead drug candidate?
Coeptis Therapeutics Holdings Inc.'s most advanced tracked candidate is Bortezomib (Phase 2) for Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Stem Cell Transplantation.
What is Coeptis Therapeutics Holdings Inc.'s next catalyst?
Coeptis Therapeutics Holdings Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: XPOVIO" — expected August 14, 2035.
What is Coeptis Therapeutics Holdings Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Coeptis Therapeutics Holdings Inc. has approximately 9.3 months of cash runway.
What is Coeptis Therapeutics Holdings Inc.'s market capitalization?
Coeptis Therapeutics Holdings Inc.'s market capitalization is approximately $102.1M.
Get the full picture on Coeptis Therapeutics Holdings Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.